| | Business Summary | | Millennium
Pharmaceuticals,
Inc.
incorporates
large-scale
genetics,
genomics,
high-throughput
screening
and
informatics
in
an
integrated
science
and
technology
platform.
Millennium
applies
this
technology
platform
primarily
in
discovering
and
developing
proprietary
therapeutic
and
diagnostic
human
healthcare
products
and
services.
Since
inception,
substantially
all
of
the
Company's
revenues
have
been
derived
from
its
strategic
alliances.
The
Company's
business
is
built
around
three
principal
areas
of
focus,
technology,
therapeutics
and
predictive
medicine. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Millennium
Pharmaceutical
is
engaged
in
the
commercial
application
of
genetics,
genomics
and
bioinformatics
to
discover
and
develop
a
broad
range
of
novel
therapeutic
and
diagnostic
products.
For
the
six
months
ended
6/30/01,
revenues
increased
17%
to
$109.4
million.
Net
loss
applicable
to
Common
before
acct.
change
decreased
13%
to
$99.8
million.
Results
reflect
increased
revenue
from
Aventis
and
Bayer,
partially
offset
by
higher
R&D
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Mark Levin, 50
Chairman,
CEO and Pres | $408K | -- | Kevin Starr, 38
CFO,
Exec. VP of Bus. Operations | 291K | $8.7M | Robert Tepper, M.D., 45
Exec.
VP of Discovery, CSO | 305K | -- | Kenneth Conway, 52
Sr.
VP, Pres of MPMx | -- | -- | John Douglas, III, 47
Sr.
VP, Gen. Counsel | 331K | 8.1M | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/m/mlnm.gif)